Vanguard Investments Australia
KALV

Vanguard Investments Australia’s KalVista Pharmaceuticals KALV Stock Holding History

Vanguard Investments Australia’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,650
Closed -$174K – 2403
2026
Q1 		$174K Buy
+8,650
New +$139K ﹤0.01% 2101

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Investments Australia's KALV Position: Q2 2026 in Review

Vanguard Investments Australia sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 8,650 shares — an estimated $174K sold.

Vanguard Investments Australia first reported a position in KALV in Q1 2026 and held it in 1 quarter. The position peaked at $174K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Vanguard Investments Australia reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Investments Australia sold 8,650 KalVista Pharmaceuticals shares in Q2 2026, an estimated $174K.
  • Vanguard Investments Australia first reported a position in KalVista Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Investments Australia's KalVista Pharmaceuticals position peaked at $174K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.